Professor Fatima Cardoso is the Director of the Breast Unit of the Champalimaud Cancer Clinical in Lisbon, Portugal. Professor Cardoso earned her medical degree at the University of Porto in Portugal and completed fellowships in the Translational Research Unit of the Jules Bordet Institute (IJB) in Brussels, Belgium, and the Department of Molecular and Cellular Oncology at MD Anderson Cancer Center in Houston, Texas. She then worked for 10 years as Assistant Professor at the Medical Oncology Clinic of the IJB where, besides her clinical work, she was active in the Translational Research Unit and was responsible for phase II-III trials in breast cancer.

Professor Cardoso is board certified in medical oncology and internal medicine. Professor Cardoso’s research interests include biology of breast cancer, prognostic and predictive markers of response to systemic therapy, and new anticancer agents. She is actively involved in a number of phase I-III breast cancer clinical trials and served as the scientific Director of the international research network TRANSBIG for 7 years (EU Framework VI).

Professor Cardoso is also actively involved in numerous professional organisations such as the European Society of Medical Oncology (ESMO), the European Cancer Organization (ECCO), EORTC, ASCO, and AACR where she serves on several committees, is a Board Member and Chair of the National Representatives Committee of ESMO, the current Chair of the EORTC-Breast Cancer Group, member of the ASCO International Affairs Committee and ASCO Breast Cancer Guideline Advisory Group. She is also the Breast Cancer Program Coordinator of the European School of Oncology and Chair of the Advanced Breast Cancer International Consensus Guidelines Conference (ABC).

Professor Cardoso is editor-in-chief of The Breast Journal, associate editor of the European Journal of Cancer, and an editorial board member of several other journals. She has received several educational and research grants from the Breast Cancer Research Foundation, ESMO, ECCO, the Portuguese Science and Technology Foundation, the Portuguese League Against Cancer, the Portuguese Ministry of Health, the Free University of Brussels, the "Fonds Jean-Claude Heuson", the Fondation Lambeau-Marteau, the Belgian Federation Against Cancer, the Susan G. Komen Foundation, and the European Union Framework VI Programme. She was awarded the prestigious Order of Santiago de Espada for Scientific Merit from the President of Portugal on 10 June 2015. Professor Cardoso has authored over 230 publications and has presented her work nationally and internationally.

Professor Matthew J. Ellis is the Director of the Lester and Sue Smith Breast Center, Director and Professor of Medicine and Cellular and Molecular Biology at the Baylor College of Medicine Houston, Texas. In these roles he coordinates an interdisciplinary team of oncologists, pathologists, epidemiologists, basic scientists and statisticians focused on improving the prevention, detection and treatment of breast cancer. In addition he is an Associate Director for Translational Research at the Dan L. Duncan Cancer Center, Baylor College of Medicine with a broad role in promoting translational research.

Professor Ellis’ research focuses on estrogen receptor positive (ER+) breast cancer. He has championed neoadjuvant endocrine therapy as a non-toxic alternative to chemotherapy for promoting breast-conserving therapy in postmenopausal women with ER+ HER2- stage 2 and 3 disease. He developed the Ki67 proliferation marker-based Preoperative Endocrine Prognostic Index (Journal of Clinical Oncology 2017) which is now undergoing a large validation study (the ALTERNATE study). These clinical studies have provided the clinical context and tumour specimens for seminal investigations into the ER+ breast cancer somatic genome, with insights into massive clonal heterogeneity (Nature Communications 2015), new tumour suppressor gene discovery specific to ER+ disease and new therapeutic targets (Nature 2012). These include activating mutations in the HER2 gene that have been shown respond to HER2 kinase inhibition in clinical trials, particularly metastatic lobular carcinoma (Cancer Discovery 2013).

Professor Ellis also pioneered patient-derived xenograft research (PDX). A PDX study in triple negative breast cancer revealed clonal Remodelling during brain metastasis (Nature 2010). PDX analysis also revealed acquired resistance to endocrine therapy is a consequence of ESR1 ligand-binding mutation; ESR1 amplification and most uniquely chromosomal translocation causing fusions between the N terminus of ESR1 and the C-terminus of genes that can confer constitutive transcriptional activity (Cell Reports 2013). Professor Ellis was the recipient of ASCO's 2015 Gianni Bonadonna Breast Cancer Award and Lecture for his pioneering research into the clinical relevance of activating mutations in HER2 and in the deployment of patient-derived xenografts for the pharmacological annotation of breast cancer genomes.

He is currently Co-Chair of the translational medicine committee for the NRG cooperative group, co-leader for The Cancer Genome Atlas (TCGA) Breast Project and also serves as a Co-PI for the Clinical Proteomic Tumor Analysis Consortium that endeavours to translate TCGA genomic discoveries into protein-based biomarkers with clinical utility. This mass spectrometry based approach recently elucidated the functional consequences of somatic mutations, narrowed candidate nominations for driver genes within large deletions and amplified regions and identified therapeutic targets.

Dr Christopher Jackson is a Consultant Medical Oncologist with the Southern Blood and Cancer Service (Southern DHB) and Senior Lecturer in Medicine with the University of Otago in New Zealand. In 2015 he was appointed as Medical Director of the Cancer Society of New Zealand.

After undertaking initial training in New Zealand, Dr Jackson undertook his fellowship at the Royal Marsden Hospital in London, training in gastrointestinal cancers, lymphoma, and urological cancers. He later held a post as a Locum Consultant at the Trust. Since returning to New Zealand Dr Jackson has been active in clinical research and in cancer policy. He was clinical lead for New Zealand’s largest colorectal cancer study, the PIPER project. He is also Deputy Director of Cancer Trials New Zealand, leads clinical research at Southern DHB, and is a lead investigator in the Centre for Translational Cancer Research and for the National Science Challenges Healthier Lives. In the policy area he is Chair of the Colorectal Cancer Tumour Standards Group, and serves on the National Bowel Cancer Group and Medical Oncology Work Group.

Currently Dr Jackson coordinates undergraduate and postgraduate teaching for oncology at the Dunedin School of Medicine, is principal investigator developing an oral anti-cancer drug called Oraxol, and continues with his bowel cancer outcomes work with the PIPER project.

Professor Hyman B. Muss is the Mary Jones Hudson Distinguished Professor of Geriatric Oncology at the University of North Carolina (UNC) School of Medicine, and the Director of the Geriatric Oncology Program at the UNC Lineberger Comprehensive Cancer Center Program. An experienced clinician-scientist his interest is education and research focuses on cancer in older patients and he is regarded as an internationally recognised leader in this area. His particular interest and research expertise is in the care of breast cancer patients with a focus on the management of older women. Professor Muss also has a major interest in breast cancer survivorship and the long-term toxicity of treatment. With his UNC colleague, Professor Ned Sharpless, he is exploring the role of the biomarkers of ageing and their potential role as predictors of toxicity and survival.

Professor Muss has developed and been PI on multiple clinical and translational trials including lead author of an National Cancer Institute-sponsored intergroup trial that compared standard care with oral chemotherapy in older women with early stage breast cancer and which for the first time showed the value of chemotherapy in this older populations.

He serves as the mentor for medical students, medicine residents, junior faculty, and most recently three Geriatric Oncology fellows. He currently co-chairs the Alliance Committee on Cancer in the Elderly. He has been co-chair of the Breast Committee for the CALGB, Chair and a member of the board of Directors of the American Board of Internal Medicine, and a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and the ASCO Foundation. He was awarded the B.J. Kennedy Award in Geriatric Oncology by ASCO, and the Susan G. Komen for the Cure Brinker Award for Scientific Distinction in Clinical Research. He has served in the U.S. Army in Vietnam where he was awarded the Bronze Star medal. February 16, 2016.

Professor Sebastian Stintzing, is a senior physician in the Department of Haematology and Oncology at the University Hospital Munich, Germany. His research focuses on predictive and prognostic biomarkers in the treatment of colorectal cancer.

Professor Stintzing received his medical degree from the Friedrich-Alexander University of Erlangen-Nuremberg, completed his internship and started residency at the Department of Gastroenterology, Pulmonology and Hepatology at the University Hospital in Erlangen (with Professor E. Hahn). During this time he was a research fellow at the Laboratory for Hepatology and Oncology at the Department of Gastroenterology (with Professor. M. Ocker). He specialised at the Department of Haematology and Oncology at the Hospital Grosshadern at the Ludwig-Maximilians University of Munich (with Professor W. Hiddemann) where he joined the research group “Oncology” (“FIRE-group”) (with Professor V. Heinemann).

Professor Stintzing coordinated the translational component and assisted the clinical study conduct of several studies (AIO KRK-0104, AIO KRK-0306, AIO KRK-0110, AIO KRK-0114) and earned his Postdoctoral Lecture Qualification (Habilitation) with a thesis on prognostic and predictive factors in the treatment of metastatic colorectal cancer in 2012. In 2012 he received the prestigious Research Fellowship Award from the “Deutsche Krebshilfe” (German Cancer Aid) enabling him to work as a research fellow at the Sharon Carpenter Laboratory at the USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles (Prof H.-J. Lenz) from 2012 -2014. In 2014 he received the scientific award of the AIO (medical oncology working group within the German Cancer Society).

Professor Stintzing is member of several national and international cancer associations and since 2012 a member of the steering committee of the working group “Colorectal Carcinoma” of the German AIO. Since 2014 he has been a member of the treatment guideline committee for colorectal cancer in Germany.